Category: Pharmaceuticals
-
Valeo Pharma Inc. (VPH.C) – THE undervalued biotech play
If you’re one of the discerning readers who bought Valeo Pharma’s stock since the last article I posted on July 6th, 2020: congratulations you should be making over 38% returns on your investment. Better yet, if you had bought Valeo’s stock a month ago, you would have been up close to 184%, which, y’know, is…
-
Biotech: Who will survive when the Covid-19 Hype Ends? Part II
For part I of this series please click here. Cities across Canada are gradually returning to business as usual, and we’re winning the fight against Covid-19 (don’t look south of the border). Thanks to all citizens still wearing hats to hide their botched home-haircuts, and our essential workers who literally put their lives on the…
-
Roadman Investments (LITT.V) really doesn’t want to talk about cedar leaf oil anymore
One of Roadman Investments (LITT.V) subsidiaries, CLOV Biopharma, recently completed its research program at UBC on cedar leaf oil vapour, but the Securities Exchange Commission (SEC) doesn’t care. The research program has taken a bit longer than the company would have liked, courtesy of COVID-19, but the company’s doctors have acquired most of the exemptions…
-
![Algernon Pharmaceuticals (AGN.C) gets ethical green light for human trials for COVID-19 fighter Ifenprodil]()
Algernon Pharmaceuticals (AGN.C) gets ethical green light for human trials for COVID-19 fighter Ifenprodil
The scientific process isn’t exactly what you were taught in grade 4. There’s a lot more to it, owing to some historical—well, let’s call them what they are—atrocities, which have taken place as long as white lab-coats have been all the rage in knowledge-defining circles. This process is expensive in both time and money and…
-
I asked Twitter what tickers I should be writing about: Twitter had 35 ideas… here’s 6 of them
Ever get the feeling, looking at your watchlist, that you’re seeing the same thing over and over? That maybe there’s interesting stuff out there you just haven’t heard about yet? I put a simple question to Twitter today: “Give me a ticker symbol you think I should be writing about (limit one per person), three…
-
Biotech: Who Will Survive When The COVID-19 Hype Ends?
Over the last couple of months, companies have found a way to muster up an effort to align their objectives with helping society recover from this global pandemic – COVID-19. The result: share prices have soared like never before. The line up of biotech companies trying to come up with COVID-19 vaccines or cures is…
-
Everything is up: Eat, drink, be merry… for tomorrow we die
When the history books are written on this passage of our lives, under pandemic lockdown and with once-in-three-generations levels of unemployment, they’ll note that in order to save us from economic collapse, the government printed trillions of dollars and just fired it all into the markets out of a bazooka, only to establish a decades-long…
-
![PredictMedix: Pharma Monopoly Meets Tech Growth]()
PredictMedix: Pharma Monopoly Meets Tech Growth
Here’s a simple and effective investment strategy: invest in companies that sell products with growing inelastic demand.
-
Revive Therapeutics (RVV.C): Kicked around, called a fraud, gets FDA approval of Phase 3 COVID-19 trials
“Let them say what they want, we know what we’re doing, and we’re doing the work,” Michael Frank told me a month ago, as he put out news claiming his little pharma company, which had built a reputation for chasing aggressively into new pharmaceutical fields, had found some IP that might be useful in the…
-
Revive Therapeutics (RVV.C) warned about overhype, but up 26% on clinical trial news
Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts…
